OncLive SOSS

Authors

Everett Vokes, MD, University of Chicago Medicine

Eytan M. Stein, MD

Eytan M. Stein, MD, is the Chief of the Leukemia Service, Associate Attending Physician, Clinical Investigator, and Director of the Program for Drug Development

Latest:

Dr Stein on the FDA Approval of Revumenib for R/R, NPM1-Mutant AML

Eytan M. Stein, MD, discusses the significance of the FDA approval of revumenib as a targeted therapy for relapsed/refractory, NPM1-mutant AML.

Eytan Stein, MD

Latest:

Dr Stein on the Efficacy of Revumenib in KMT2A+ R/R Acute Leukemia

Eytan M. Stein, MD, discusses efficacy findings from the phase 1/2 AUGMENT-101 study of revumenib in KMT2A-rearranged relapsed/refractory acute leukemia.

Latest:

Dr. Cohen on Future Research Directions in Head and Neck Cancer

Ezra Cohen, MD, FRCPSC, FASCO, discusses future research directions for the treatment of patients with head and neck cancer.

Ezra Cohen, MD, FRCPSC, FASCO, UC San Diego

Latest:

Sequencing Throughout Multiple Lines of Therapy in RR DTC

Before closing out their discussion on RR DTC management, panelists consider the advent of sequencing through multiple lines of therapy.

Ezra Cohen, MD, Moores Cancer Center

Ezra Cohen, MD, UC San Diego Moores Cancer Center

Ezra Cohen, MD, UCSD

Ezra Cohen, MD, University of Chicago

Ezzat Elhassadi, MD

Latest:

Dr. Elhassadi on the Subtypes of MCL

Ezzat Elhassadi, MD, consultant hematologist, Hematology Services, University Hospital Waterford, discusses the subtypes of mantle cell lymphoma (MCL).

F. Anthony Greco, MD, Sarah Cannon Cancer Center

F. Nery Flores, MD

Latest:

Focal Therapy Evolves Into More Precise Treatment in Prostate Cancer

Historically, the management of localized prostate cancer has centered on removal or ablation of the entire gland with either extirpative surgery or radiation. However, the subsequent unacceptable adverse events profile can be devastating and life altering for many patients.

F. Stephen Hodi, MD

Latest:

Dr. Hodi on Long-Term Survival Data for Nivolumab in Melanoma

F. Stephen Hodi, MD, director of the Melanoma Center at Dana-Farber Cancer Institute, discusses the results of the longest follow-up survival study of patients with advanced melanoma who were treated with single-agent nivolumab (Opdivo).

Latest:

Dr. Andre on the Impact of the SOLAR-1 Findings in Breast Cancer

Fabrice André, MD, PhD, professor, Department of Medical Oncology, Institut Gustave Roussy, discusses the impact of the SOLAR-1 findings in breast cancer at the 2018 ESMO Congress.

Fabrice Andre, MD, PhD

Latest:

Dr. Andre on Strategies to Improve Outcomes in Breast Cancer

Fabrice André, MD, PhD, discusses strategies to improve outcomes in patients with breast cancer.

FACP, University of Pittsburgh School of Medicine

Fadi Braiteh, MD, Comprehensive Cancer Centers of Nevada

Fadi Braiteh, MD, CPI, CCC Nevada

Fadi Braiteh, MD, University of Nevada School of Medicine

Fadi S. Braiteh, MD